Core Insights - Teleflex Incorporated reported solid second quarter results with an increase in constant currency revenue growth and adjusted earnings per share compared to the prior year [3][6] - The company successfully completed the acquisition of BIOTRONIK's Vascular Intervention business, which positively impacted the 2025 adjusted constant currency revenue guidance [3][9] - The company is focused on unlocking value through the separation of NewCo and exploring options to maximize shareholder value [3] Financial Performance - For the three months ended June 29, 2025, consolidated net revenue was $780.9 million, reflecting a 4.2% increase compared to $749.7 million in the prior year [5][6] - Adjusted diluted earnings per share from continuing operations for the second quarter was $3.73, up from $3.42 in the prior year [6][10] - The company raised its full year 2025 GAAP revenue growth guidance to a range of 9.00% to 10.00% and adjusted constant currency revenue growth guidance to 7.70% to 8.70% [9][10] Revenue by Segment - In the Americas, net revenue for the three months ended June 29, 2025, was $525.7 million, a 1.9% increase from $515.6 million in the prior year [5] - EMEA segment revenue increased by 13.0% to $166.2 million, while Asia segment revenue grew by 2.3% to $89.0 million [5] - For the six months ended June 29, 2025, consolidated net revenue was $1,481.6 million, a slight decrease of 0.4% compared to $1,487.5 million in the prior year [5][6] Product Category Performance - The Interventional product category saw significant growth, with revenue increasing by 20.4% to $170.0 million for the three months ended June 29, 2025 [8] - Vascular Access revenue grew by 2.4% to $185.5 million, while Anesthesia and OEM categories experienced declines of 6.0% and 11.4%, respectively [8] - For the six months ended June 29, 2025, Interventional revenue increased by 11.5% to $307.6 million, while Anesthesia and OEM categories saw declines of 8.0% and 19.2%, respectively [8][36] Outlook - The company expects the acquisition of the Vascular Intervention business to generate approximately $204 million in revenue in the second half of 2025 [9] - The adjusted diluted earnings per share guidance for 2025 was raised to a range of $13.90 to $14.30, reflecting a year-over-year increase [10][14] - The company anticipates a positive impact of approximately 0.85% from foreign exchange rate fluctuations for the full year [9][11]

Company Overview - Teleflex has completed the acquisition of the majority of BIOTRONIK SE & Co. KG's Vascular Intervention business for €760 million, significantly enhancing its interventional access product line and global presence in cath labs [1][8] - The acquired business includes a diverse portfolio of coronary and peripheral intervention products, which are expected to bolster Teleflex's innovation pipeline [4][5] Financial Impact - The acquisition is projected to add $0.10 to Teleflex's adjusted earnings per share (EPS) in the first year, with increasing contributions in subsequent years [10] - Teleflex anticipates that the acquired products will generate revenues of €177 million ($204 million) in the second half of 2025, with a constant currency revenue growth expectation of 6% or better from 2026 onward [9] Market Context - The vascular intervention medical devices market was valued at $5.1 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 7.1% through 2033, driven by the rising prevalence of cardiovascular diseases and advancements in technology [11] Recent Developments - Teleflex has announced findings from a multinational study demonstrating the effectiveness of Arrow Chlorhexidine-Impregnated Central Venous Catheters, showing a 70.5% reduction in the incidence of CLABSI [12]

Core Viewpoint - Teleflex Incorporated has successfully completed the acquisition of substantially all of the Vascular Intervention business from BIOTRONIK SE & Co. KG, enhancing its portfolio and global presence in the cath lab and peripheral intervention market [1][3][5]. Acquisition Details - The acquisition was finalized for a cash payment of €760 million, subject to certain adjustments [2]. - The Vascular Intervention business includes a comprehensive portfolio for coronary and peripheral interventions, featuring key products such as the Pantera™ Lux™ Drug-Coated Balloon Catheter and the Orsiro™ Mission Drug Eluting Stent [3][4]. Financial Outlook - The acquired products are expected to generate revenues of €177 million ($204 million) in the second half of 2025, with an anticipated €91 million ($105 million) for the fourth quarter of 2025 [5]. - From 2026 onwards, annual constant currency revenue growth of 6% or better is expected from the acquired products [5][6]. Strategic Implications - The acquisition will allow Teleflex to invest in the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold technology, with plans for a U.S. pivotal study [4]. - The integration of the Vascular Intervention business is anticipated to enhance Teleflex's innovation pipeline and position the company to leverage emerging technologies in the market [3][4].

Core Insights - Teleflex Incorporated (TFX) reported first-quarter 2025 adjusted earnings per share (EPS) of $2.91, a decrease of 9.3% year-over-year, but exceeded the Zacks Consensus Estimate by 1% [1] - The company's net revenues fell 5% year-over-year to $700.7 million, surpassing the Zacks Consensus Estimate by 0.2% [2] Revenue Breakdown - Revenues in the Americas segment were $475.7 million, down 3.7% year-over-year [3] - EMEA segment revenues decreased 5.3% year-over-year to $151.2 million [3] - Asia segment revenues fell 12.8% to $73.8 million [4] Product Revenue Performance - Vascular Access segment revenues increased by 1.9% year-over-year to $182.4 million [5] - Interventional business revenues rose 3.2% year-over-year to $137.5 million [5] - Anesthesia segment revenues decreased 8.6% year-over-year to $86.6 million [6] - Surgical segment revenues increased by 2% year-over-year to $105.8 million [6] - Interventional Urology segment revenues fell 10.7% year-over-year to $71 million [6] - OEM revenues decreased by 26.8% year-over-year to $63.9 million [7] - Other product segment revenues increased by 4.5% year-over-year to $53.5 million [7] Margin and Profitability - Gross profit was $389.4 million, down 6.4% year-over-year, with a gross margin of 55.6%, a contraction of 82 basis points [8] - Adjusted operating profit was $130.3 million, down 4.2% year-over-year, but the adjusted operating margin expanded by 17 basis points to 18.6% [9] Liquidity and Cash Flow - Teleflex ended Q1 2025 with cash and cash equivalents of $284.1 million, down from $290.2 million at the end of Q4 2024 [10] - Net cash flow from operating activities was $73.3 million, compared to $112.8 million in the prior year [11] Updated Guidance - The company now expects GAAP revenue growth for 2025 to be in the range of 1.28-2.28%, revised from a prior guidance of a decline of 0.4% to growth of 0.7% [12] - Adjusted EPS guidance for 2025 is now projected to be between $13.20 and $13.60, down from the previous range of $13.95 to $14.35 [12] Strategic Developments - Teleflex has entered into an agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG, which will enhance its product portfolio and market presence [15] - The acquisition includes a range of vascular intervention devices, positioning the company for continued growth [15]

NEW YORK, March 30, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or the "Company") (NYSE: TFX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Teleflex and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. Attorney advertising. Prior results do not guarantee similar outcomes. C ...

Financial Data and Key Metrics Changes - For Q4 2024, Teleflex reported revenues of $795.4 million, an increase of 2.8% year-over-year on a GAAP basis and 3.2% on an adjusted constant currency basis [11] - Adjusted earnings per share grew 15.1% to $3.89 [13] - For the full year 2024, adjusted constant currency revenues increased 3.1% year-over-year, while adjusted earnings per share was $14.01 [18] Business Line Data and Key Metrics Changes - Interventional and Surgical businesses showed strong performance with adjusted constant currency growth of 18.7% and 12.3% respectively in Q4 [11] - Interventional Urology revenue increased 3.7% on an adjusted constant currency basis, with growth in Palette offset by softness in the UroLift business [19] Market Data and Key Metrics Changes - Adjusted gross margin for Q4 was 60.1%, flat year-over-year, while adjusted operating margin was 27.6%, up 130 basis points [17] - Cash flow from operations increased 24.7% year-over-year to $638.3 million in 2024 [20] Company Strategy and Development Direction - Teleflex announced a definitive agreement to acquire the Vascular Intervention business from BIOTRONIK for approximately EUR760 million, aimed at enhancing growth and market presence in the cath lab [32] - The company plans to separate into two independent publicly traded companies, RemainCo and NewCo, to optimize product portfolios and drive growth [48][49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving 6%+ revenue growth for RemainCo post-separation, despite current challenges in the UroLift and OEM businesses [106] - The guidance for 2025 anticipates adjusted constant currency growth of 1% to 2%, reflecting headwinds from UroLift and inventory management by customers [24][103] Other Important Information - A noncash goodwill impairment charge of $240 million was recognized for the Interventional Urology North America reporting unit due to subdued revenue growth [21] - The company plans to finance the acquisition through a new term-loan and revolving borrowings under its existing senior credit facility [47] Q&A Session Summary Question: What prompted the review and timing for the separation? - Management indicated that continuous portfolio reviews led to the conclusion that separating the businesses would maximize shareholder value, especially with the addition of the BIOTRONIK business [78][80] Question: How will the sales force be structured post-acquisition? - The acquisition allows for leveraging Teleflex's strong presence in the Americas and BIOTRONIK's strength in EMEA, creating opportunities for synergy [84] Question: What is the growth outlook for the acquired assets? - The acquired portfolio is expected to deliver a constant currency revenue CAGR of 5.4% since 2022, with expectations for growth to exceed 6% post-acquisition [94] Question: What are the expected margins for RemainCo and NewCo? - RemainCo is expected to grow at 6%+ with mid-60s gross margins, while NewCo is anticipated to grow in the low single digits with mid-50s gross margins [118] Question: How will the capital structure be managed post-separation? - The capital structure for both companies will be defined in the coming quarters, with a focus on ensuring both have strong, viable futures [121]

Core Viewpoint - Teleflex Incorporated has announced a definitive agreement to acquire the Vascular Intervention business of BIOTRONIK SE & Co. KG for approximately €760 million, aiming to enhance its presence in the interventional cardiology and peripheral vascular market, which is estimated to be worth $10 billion [1][2]. Group 1: Acquisition Details - The acquisition is expected to close by the end of the third quarter of 2025, subject to customary closing conditions and regulatory approvals [1]. - The acquired business will expand Teleflex's portfolio to include a range of vascular intervention devices, with 75% of the acquired revenues coming from coronary interventions and 25% from peripheral procedures [2][3]. - Key products in the acquired portfolio include drug-coated balloons, drug-eluting stents, and various stent types for both coronary and peripheral interventions [2]. Group 2: Strategic Implications - The acquisition is anticipated to significantly enhance Teleflex's global presence in the cath lab and improve patient care through an expanded suite of innovative technologies [2]. - The integration of BIOTRONIK's products is expected to complement Teleflex's existing complex percutaneous coronary intervention (PCI) platform and diversify its geographic revenue mix, with 50% of the acquired revenues generated in EMEA [2][3]. - Teleflex plans to leverage its established education and clinical platforms to further enhance the offerings to cardiac and peripheral care specialists [4][5]. Group 3: Financial Outlook - The acquired products are projected to generate approximately €91 million in revenues in the fourth quarter of 2025, with expected constant currency revenue growth of 6% or better starting in 2026 [6][7]. - The transaction is expected to be approximately $0.10 accretive to Teleflex's adjusted earnings per share in the first year of ownership, with increasing accretion thereafter [8]. - Teleflex intends to finance the acquisition through a new term loan, revolving borrowings, and cash on hand, while also entering into foreign exchange derivative contracts to hedge against currency exposure [9][8].